Out of Warburg effect: An effective cancer treatment targeting the tumor specific metabolism and dysregulated pH - PubMed
Review
Out of Warburg effect: An effective cancer treatment targeting the tumor specific metabolism and dysregulated pH
Laurent Schwartz et al. Semin Cancer Biol. 2017 Apr.
Abstract
As stated by Otto Warburg nearly a century ago, cancer is a metabolic disease, a fermentation caused by malfunctioning mitochondria, resulting in increased anabolism and decreased catabolism. Treatment should, therefore, aim at restoring the energy yield. To decrease anabolism, glucose uptake should be reduced (ketogenic diet). To increase catabolism, the oxidative phosphorylation should be restored. Treatment with a combination of α-lipoic acid and hydroxycitrate has been shown to be effective in multiple animal models. This treatment, in combination with conventional chemotherapy, has yielded extremely encouraging results in glioblastoma, brain metastasis and lung cancer. Randomized trials are necessary to confirm these preliminary data. The major limitation is the fact that the combination of α-lipoic acid and hydroxycitrate can only be effective if the mitochondria are still present and/or functional. That may not be the case in the most aggressive tumors. The increased intracellular alkalosis is a strong mitogenic signal, which bypasses most inhibitory signals. Concomitant correction of this alkalosis may be a very effective treatment in case of mitochondrial failure.
Keywords: ATP; Intracellular alkalosis; Ketogenic diet; Metabolic treatment; Unification theory; Warburg’s effect.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
The Warburg Effect and the Hallmarks of Cancer.
Schwartz L, Supuran CT, Alfarouk KO. Schwartz L, et al. Anticancer Agents Med Chem. 2017;17(2):164-170. doi: 10.2174/1871520616666161031143301. Anticancer Agents Med Chem. 2017. PMID: 27804847 Review.
-
Metabolic treatment of cancer: intermediate results of a prospective case series.
Schwartz L, Buhler L, Icard P, Lincet H, Steyaert JM. Schwartz L, et al. Anticancer Res. 2014 Feb;34(2):973-80. Anticancer Res. 2014. PMID: 24511042
-
Schwartz L, Abolhassani M, Guais A, Sanders E, Steyaert JM, Campion F, Israël M. Schwartz L, et al. Oncol Rep. 2010 May;23(5):1407-16. doi: 10.3892/or_00000778. Oncol Rep. 2010. PMID: 20372858
-
Decoding Warburg's hypothesis: tumor-related mutations in the mitochondrial respiratory chain.
Garcia-Heredia JM, Carnero A. Garcia-Heredia JM, et al. Oncotarget. 2015 Dec 8;6(39):41582-99. doi: 10.18632/oncotarget.6057. Oncotarget. 2015. PMID: 26462158 Free PMC article. Review.
Cited by
-
Viedma-Rodríguez R, Martínez-Hernández MG, Martínez-Torres DI, Baiza-Gutman LA. Viedma-Rodríguez R, et al. Horm Cancer. 2020 Aug;11(3-4):170-181. doi: 10.1007/s12672-020-00389-z. Epub 2020 Jun 16. Horm Cancer. 2020. PMID: 32557212 Free PMC article.
-
Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells.
Wang X, Xuetao X, Wu M, Wu P, Sheng Z, Liu W, Ma YY, Zhao DG, Zhang K, Li D, Zheng X, Goodin S. Wang X, et al. J Enzyme Inhib Med Chem. 2022 Dec;37(1):542-553. doi: 10.1080/14756366.2021.2018684. J Enzyme Inhib Med Chem. 2022. PMID: 34986722 Free PMC article.
-
Pan CT, Yu RS, Yang CJ, Chen LR, Wen ZH, Chen NY, Ou HY, Yu CY, Shiue YL. Pan CT, et al. Pharmaceutics. 2021 Sep 7;13(9):1417. doi: 10.3390/pharmaceutics13091417. Pharmaceutics. 2021. PMID: 34575492 Free PMC article.
-
Xu D, Wang Y, Wu J, Zhang Z, Chen J, Xie M, Tang R, Chen C, Chen L, Lin S, Luo X, Zheng J. Xu D, et al. Cell Death Dis. 2021 Feb 8;12(2):162. doi: 10.1038/s41419-021-03450-z. Cell Death Dis. 2021. PMID: 33558466 Free PMC article.
-
The Prime and Integral Cause of Cancer in the Post-Warburg Era.
Harguindey S, Reshkin SJ, Alfarouk KO. Harguindey S, et al. Cancers (Basel). 2023 Jan 16;15(2):540. doi: 10.3390/cancers15020540. Cancers (Basel). 2023. PMID: 36672490 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials